Contract analysis

I. Executive Summary This memorandum analyzes the potential remedies that the Federal Trade Commission ("FTC") may require to address the horizontal competitive overlap arising from Ardent Capital Partners III LP's ("Fund III") simultaneous ownership — through its sponsor group's affiliated funds — of Vectis Solutions LLC ("Vectis"), an existing portfolio company of Ardent Capital Partners II LP ("Fund II"), and Lumi

1. Full divestiture of Vectis Solutions LLC — the sale of 100% of Fund II's equity interest in Vectis to an FTC-approved purchaser, either prior to or concurrent with the closing of the Luminex acquisition.

2. Partial divestiture of overlapping product lines or assets — a carve-out of specific product lines, customer segments, or assets within either Luminex or Vectis that directly overlap, while retaining the non-overlapping components of each business.

3. Behavioral or conduct remedies — structural separation measures such as firewall agreements, independent management requirements, pricing commitments, and FTC-monitored compliance programs, without any asset disposition. Bottom-line assessment. Full divestiture of Vectis is the most likely remedy that the FTC would accept if the Commission determines that the Luminex-Vectis overlap is competitively problematic. Th

II. Background A. The Transaction Ardent Capital Partners III LP ("Fund III"), a Delaware limited partnership with its principal offices at 399 Park Avenue, 42nd Floor, New York, NY 10022, is acquiring Luminex Systems Holdings Inc. ("Luminex" or the "Target"), a Delaware corporation headquartered at 2100 Reston Gateway Drive, Suite 800, Reston, Virginia 20191, through a reverse triangular merger under the Delaware Ge

III. FTC Analytical Framework A. Substantive Standard The FTC's authority to challenge the Transaction derives from Section 7 of the Clayton Act (15 U.S.C. § 18), which prohibits acquisitions where "the effect of such acquisition may be substantially to lessen competition, or to tend to create a monopoly" in any relevant market. Section 7 is an incipiency statute — it is designed to arrest anticompetitive trends in t

1. Guideline 1 — Market Concentration. Mergers should not significantly increase concentration in highly concentrated markets. A market is "highly concentrated" where the post-merger HHI exceeds 1,800. A merger "significantly increases concentration" where the change in HHI exceeds 100. As noted above, the post-merger HHI in the procurement-automation SaaS market is estimated at approximately 1,532, which falls below

2. Guideline 2 — Head-to-Head Competition. Mergers should not eliminate substantial competition between firms. This guideline focuses on direct competitive rivalry between the merging parties. The FTC will examine whether Luminex and Vectis compete head-to-head for the same procurement-automation SaaS customers and whether the elimination of that competition would harm customers. Evidence of direct competition — incl

3. Guideline 7 — Serial Acquisitions and Industry Roll-Ups. The 2023 Merger Guidelines introduced a new guideline specifically addressing patterns of serial acquisitions. The FTC will evaluate whether the Transaction, viewed in the context of Ardent's existing ownership of Vectis, is part of a pattern of acquisitions that individually or collectively may substantially lessen competition. This guideline is particularl

1. Distinct customer segments. Luminex and Vectis serve largely different customer populations. Luminex One is primarily marketed to large enterprise customers, particularly multinational corporations with complex, cross-border procurement and supply-chain operations. Its strongest market presence is in the DACH region and among Fortune 500 companies. Vectis, by contrast, is a mid-market-focused solution predominantl

2. Product differentiation. Luminex One is a full-suite ERP/procurement/supply-chain platform, while Vectis is a point solution focused exclusively on procurement automation. From a product-architecture standpoint, these are fundamentally different offerings. Customers selecting Luminex One are typically seeking a comprehensive, integrated enterprise platform, while customers selecting Vectis are typically seeking a

3. Acquisition-specific efficiencies. Ardent's acquisition of Luminex is expected to generate acquisition-specific efficiencies through the combination of Luminex's platform capabilities with Ardent's operational expertise in scaling enterprise SaaS businesses. These efficiencies — including investments in product development, expansion into new geographic markets, and operational improvements — are not achievable ab

4. Substantial remaining competition. Even at a combined market share of approximately 25%, the post-merger market would remain competitive, with at least five other significant players (Westmark Partners LLC, Meridian Corporation, Ostrander Industries, Halcyon Holdings, and Cobalt Ridge Holdings) collectively holding approximately 62% of the market. No single firm would dominate the market, and customers would retai

IV. Remedy Scenario Analysis We have identified and evaluated three principal remedy scenarios that may be pursued to resolve the FTC's competitive concerns. Each scenario is analyzed below in terms of its description, feasibility, financial implications, advantages, and disadvantages. A. Scenario 1: Full Divestiture of Vectis Solutions LLC

1. Description. Under this scenario, Ardent would sell 100% of its equity interest in Vectis Solutions LLC — held by Ardent Capital Partners II LP (Fund II) — to an FTC-approved purchaser, either prior to or concurrent with the closing of the Luminex acquisition. The divestiture would encompass all of the assets of the Vectis business as a going concern, including: • The Vectis procurement-automation SaaS platform, i

2. Estimated Valuation and Financial Impact The financial implications of a full Vectis divestiture are summarized as follows: Vectis valuation. Vectis generated total revenue of $68,000,000 in fiscal year 2024. Applying comparable enterprise-value-to-revenue multiples for procurement-SaaS companies, which generally range from approximately 4.0x to 6.0x revenue based on recent transaction precedents and public-compan

3. Process Considerations FTC consent decree requirements. In a typical FTC consent decree involving a divestiture remedy, the Commission imposes detailed requirements designed to ensure that the divested business remains a viable and effective competitor in the relevant market. These requirements typically include: • The purchaser must have the financial capability to operate and invest in the divested business on a

4. Advantages. • Cleanest remedy. A full Vectis divestiture eliminates the competitive overlap entirely. There is no residual issue of common ownership in the procurement-automation SaaS market, and no ongoing compliance obligations or monitoring requirements. • Most likely to satisfy FTC quickly. Given the FTC's strong preference for structural remedies and its skepticism of behavioral alternatives, a full Vectis di

5. Disadvantages. • Loss of a valuable portfolio asset for Fund II. Vectis is a high-growth procurement-SaaS business with substantial value. A forced divestiture deprives Fund II's limited partners of the future upside potential of the investment, including the possibility that Vectis could be grown and eventually sold or taken public at a higher valuation. • Potential fire-sale discount. If the Vectis sale is condu

1. Description. Under this scenario, rather than divesting Vectis in its entirety, Ardent would divest only the specific product lines, customer segments, or assets within either Luminex or Vectis that directly overlap with the other company's offerings. This approach seeks to preserve maximum value across both portfolio companies while addressing the FTC's competitive concerns in a targeted manner. We have identifie

2. Feasibility Assessment Option 2A — Luminex procurement module carve-out. This option presents formidable technical and commercial challenges. The procurement-automation functionality within Luminex One is deeply integrated into the platform's architecture. The procurement module shares a common data model, user interface framework, authentication and security infrastructure, and application programming interfaces

3. Advantages. • Preserves partial value of both portfolio companies. If executed successfully, a partial divestiture would allow Ardent to retain portions of both the Luminex and Vectis businesses, preserving value for both Fund III and Fund II investors. • Targeted remedy. A partial divestiture addresses only the specific area of overlap, rather than requiring a wholesale disposition of an entire portfolio company.

4. Disadvantages. • Execution complexity and cost. Carving out product lines or customer segments from an integrated software business requires extensive technical work, including data migration, code separation, transition services agreements, IP licensing arrangements, and employee transfers. These processes are time-consuming, expensive, and prone to error. • FTC skepticism. The FTC has historically viewed partial

1. Description. Under this scenario, Ardent would not divest any assets. Instead, it would agree to implement behavioral or conduct-based measures designed to maintain competitive independence between Luminex and Vectis while both remain under common Ardent ownership. The specific behavioral remedies that could be proposed include: • Firewall agreements. Ardent would establish formal information barriers between the

2. FTC Receptiveness Our assessment of the current FTC's receptiveness to behavioral remedies in this case is highly unfavorable. Several factors support this conclusion: • Current FTC leadership strongly disfavors behavioral remedies. The FTC Chair and a majority of the Commissioners have publicly stated — in speeches, policy statements, and written concurrences — that structural remedies (divestitures) are the pref

3. Advantages. • No asset disposition required. Ardent retains ownership of both Luminex and Vectis, preserving the investment thesis for both Fund III and Fund II. • Preserves fund economics. Both Fund II (Vectis) and Fund III (Luminex) achieve their target returns without the dilution caused by a forced divestiture at a potentially suboptimal valuation.

4. Disadvantages. • FTC highly unlikely to accept. As discussed above, the current enforcement environment makes FTC acceptance of behavioral-only remedies exceedingly improbable in this case. • Ongoing compliance burdens. Even if behavioral remedies were accepted, they would impose significant ongoing compliance costs and operational burdens on Ardent, Luminex, and Vectis for the duration of the consent decree (pote

V. Impact on Merger Agreement Provisions A. Regulatory Efforts Covenant The Merger Agreement imposes a "reasonable best efforts" obligation on Buyer (Ardent Apex Holdings Inc.) to obtain all required governmental and regulatory approvals, including FTC clearance under the HSR Act. This covenant is set forth in Section 6.04 of the Merger Agreement and requires Buyer to take commercially reasonable actions to obtain cl